Luxturna and other Spark pipeline candidates use an adeno-associated virus vector (AVV) platform to deliver its gene therapy, a distinct technology which Novartis hasn’t built up expertise in.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback